Research programme: anti-infectives - Avidex/BioFocus/Vernalis

Drug Profile

Research programme: anti-infectives - Avidex/BioFocus/Vernalis

Alternative Names: Anti-infectives research programme - Avidex/BioFocus/Vernalis

Latest Information Update: 10 Apr 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Avidex; BioFocus DPI; Vernalis
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bacterial infections; Viral infections

Most Recent Events

  • 31 Mar 2014 BioFocus DPI has been acquired by Charles River Laboratories
  • 06 Oct 2006 Avidex has been acquired by MediGene AG
  • 30 Sep 2004 Discontinued - Preclinical for Bacterial infections in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top